GARDP and Evotec announce new partnership to discover novel antibiotics

(Drugs for Neglected Diseases Initiative) The Global Antibiotic Research and Development Partnership (GARDP) and Evotec AG have formed a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance. By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections. This includes bringing together GARDP's clinical expertise and sustainable access commitment with Evotec's leading drug discovery platform, expertise in medicinal chemistry and pharmacology as well as its world-leading collection of bacterial pathogens.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news